Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 2:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 5,340 matching trials from the live ClinicalTrials.gov search.
Filters: Milwaukee, Wisconsin Clear all
Completed Phase 3 Interventional Results available

Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS)

NCT04577404
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
MT-1186
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
13
States / cities
Phoenix, Arizona • Rogers, Arkansas • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 17, 2026, 2:28 PM EDT
Active, not recruiting Phase 3 Interventional

Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

NCT03007147
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia, T Acute Lymphoblastic Leukemia
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Calaspargase Pegol, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Dexrazoxane Hydrochloride, Doxorubicin, Etoposide, Filgrastim, Ifosfamide, Imatinib Mesylate, Laboratory Biomarker Analysis, Leucovorin Calcium, Levoleucovorin, Mercaptopurine, Methotrexate, Methylprednisolone, Pegaspargase, Prednisolone, Questionnaire Administration, Therapeutic Hydrocortisone, Thioguanine, Vincristine Sulfate
Procedure · Drug · Biological + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 21 Years
Enrollment
352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2034
U.S. locations
184
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 145 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 17, 2026, 2:28 PM EDT
Completed No phase listed Observational

Peds SM-THINk: Nursing Interventions to Improve Discharge Outcomes

NCT03539978
View directory record Official record
Conditions
Pediatric ALL
Interventions
SM-THINk
Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
Up to 100 Years
Enrollment
486 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Oct 17, 2026, 2:28 PM EDT
Active, not recruiting Not applicable Interventional

Edwards PASCAL CLASP IID/IIF Pivotal Clinical Trial

NCT03706833
View directory record Official record
Conditions
Degenerative Mitral Valve Disease, Mitral Regurgitation, Mitral Insufficiency, Functional Mitral Regurgitation
Interventions
Edwards PASCAL System, Abbott Mitraclip System
Device
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
18 Years and older
Enrollment
1,247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2031
U.S. locations
63
States / cities
Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 50 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 17, 2026, 2:28 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Role of Endothelial Dysfunction on Exercise Pressor Reflex in Type 2 Diabetes

NCT07228208
View directory record Official record
Conditions
Type 2 Diabetes (T2DM), Endothelial Dysfunction
Interventions
MitoQ (mitoquinol mesylate), Placebo
Dietary Supplement
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 17, 2026, 2:28 PM EDT
Terminated Phase 1 Interventional Results available

Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

NCT02669264
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
ADCT-402
Drug
Lead sponsor
ADC Therapeutics S.A.
Industry
Eligibility
12 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
10
States / cities
La Jolla, California • New Haven, Connecticut • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated May 24, 2021 · Synced Oct 17, 2026, 2:28 PM EDT
Completed Phase 2 Interventional

A Study of Safety, Tolerability, and Evidence of Activity of FCFD4514S Administered Monthly or Every Other Month to Patients With Geographic Atrophy

NCT01229215
View directory record Official record
Conditions
Geographic Atrophy
Interventions
FCFD4514S, sham
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
60 Years to 89 Years
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
30
States / cities
Tucson, Arizona • Beverly Hills, California • San Francisco, California + 26 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 17, 2026, 2:28 PM EDT
Completed Phase 2 Interventional Results available

Study of the Effects of Brilacidin Oral Rinse on Radiation-induced Oral Mucositis in Patients With Head and Neck Cancer

NCT02324335
View directory record Official record
Conditions
Head and Neck Neoplasms, Mucositis
Interventions
Brilacidin, Placebo
Drug · Other
Lead sponsor
Innovation Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
16
States / cities
Gilbert, Arizona • Lakeland, Florida • Columbus, Georgia + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2019 · Synced Oct 17, 2026, 2:28 PM EDT
Completed Phase 4 Interventional Results available

A Comparative Effectiveness & Long Term Health Study in Wisconsin Smokers

NCT01553084
View directory record Official record
Conditions
Smoking Cessation, Smoking, Nicotine Dependence
Interventions
Varenicline, Nicotine lozenge, Nicotine Patch
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 99 Years
Enrollment
1,086 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
2
States / cities
Madison, Wisconsin • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Oct 17, 2026, 2:28 PM EDT
Completed Phase 4 Interventional

Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab

NCT04377555
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing
Interventions
Ocrelizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
26
States / cities
Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 17, 2026, 2:28 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC

NCT02941926
View directory record Official record
Conditions
Breast Cancer
Interventions
Ribociclib, Letrozole, Goserelin, Leuprolide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
3,246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
71
States / cities
Anchorage, Alaska • Chandler, Arizona • Phoenix, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2023 · Synced Oct 17, 2026, 2:28 PM EDT
Completed Phase 3 Interventional Results available

Effect of Kuvan on Neurocognitive Function, Blood Phenylalanine Level, Safety, and Pharmacokinetics in Children With PKU

NCT00838435
View directory record Official record
Conditions
Phenylketonuria
Interventions
sapropterin dihydrochloride
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
Up to 6 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
12
States / cities
La Jolla, California • Orange, California • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2020 · Synced Oct 17, 2026, 2:28 PM EDT
Completed Phase 2 Interventional Results available

A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy

NCT01643408
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
Interventions
asparaginase Erwinia chrysanthemi
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
1 Year to 30 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
18
States / cities
Los Angeles, California • Orange County, California • Palo Alto, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Oct 17, 2026, 2:28 PM EDT
Available No phase listed Expanded access

Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Participants With Multiple Myeloma

NCT05346835
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Cilta-cel OOS Therapy
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years and older
U.S. locations
137
States / cities
Birmingham, Alabama • Gilbert, Arizona • Goodyear, Arizona + 96 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 17, 2026, 2:28 PM EDT
Approved For Marketing No phase listed Expanded access

Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma

NCT07573215
View directory record Official record
Conditions
PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Metastatic Pancreas Adenocarcinoma, Pancreatic Cancer, Pancreatic Cancer Metastatic, Pancreatic Adenocarcinoma Metastatic, Pancreatic Adenocarcinoma, Pancreatic Adenosquamous Carcinoma
Interventions
daraxonrasib
Drug
Lead sponsor
Revolution Medicines, Inc.
Industry
Eligibility
18 Years and older
U.S. locations
256
States / cities
Birmingham, Alabama • Daphne, Alabama • Dothan, Alabama + 198 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 17, 2026, 2:28 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Albiglutide in Type 2 Diabetes

NCT00849017
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
albiglutide, albiglutide uptitration, placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
247
States / cities
Alabaster, Alabama • Birmingham, Alabama • Dothan, Alabama + 205 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Oct 17, 2026, 2:28 PM EDT
Terminated Phase 2 Interventional Results available

Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer

NCT03737994
View directory record Official record
Conditions
Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Alectinib, Brigatinib, Carboplatin, Ceritinib, Cisplatin, Crizotinib, Ensartinib, Lorlatinib, Pemetrexed
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
491
States / cities
Goodyear, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 341 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 17, 2026, 2:28 PM EDT
Recruiting Not applicable Interventional

Percutaneous Intervention Versus Observational Trial of Arterial Ductus in Low Weight Infants

NCT05547165
View directory record Official record
Conditions
Ductus Arteriosus, Patent
Interventions
Percutaneous Patent Ductus Arteriosus Closure (PPC), Responsive Management Intervention, Echocardiogram, cardiac
Device · Combination Product · Diagnostic Test
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
7 Days to 32 Days
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
24
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 17, 2026, 2:28 PM EDT
Completed Phase 4 Interventional Results available

Efficacy of Intercostal CryoAnalgesia in Robotic Lung Resection

NCT05144828
View directory record Official record
Conditions
Pain, Postoperative, Lung Diseases
Interventions
Intercostal Nerve Cryoablation, Patient-controlled analgesia (PCA)
Device · Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 85 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 17, 2026, 2:28 PM EDT
Completed Phase 2Phase 3 Interventional Results available

S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer

NCT02438722
View directory record Official record
Conditions
Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
Interventions
Afatinib Dimaleate, Cetuximab, Laboratory Biomarker Analysis
Drug · Biological · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Not listed
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
638
States / cities
Fort Smith, Arkansas • Hot Springs, Arkansas • Jonesboro, Arkansas + 406 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 17, 2026, 2:28 PM EDT
No Longer Available No phase listed Expanded access

A Study to Provide Access to Trabectedin in Participants With Locally Advanced or Metastatic Soft Tissue Sarcoma Who Have Persistent or Recurrent Disease and Who Are Not Expected to Benefit From Currently Available Standard of Care Treatment

NCT00210665
View directory record Official record
Conditions
Sarcoma
Interventions
Trabectedin
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
15 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
31
States / cities
Anchorage, Alaska • San Diego, California • Santa Monica, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2017 · Synced Oct 17, 2026, 2:28 PM EDT
Completed Phase 2 Interventional Results available

Cytarabine in Treating Young Patients With Recurrent or Refractory Ewing's Sarcoma

NCT00470275
View directory record Official record
Conditions
Sarcoma
Interventions
cytarabine
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 30 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
63
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 56 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2014 · Synced Oct 17, 2026, 2:28 PM EDT
Completed Phase 3 Interventional Results available

Outcomes Following Myocardial Revascularization: On and Off Cardiopulmonary Bypass

NCT00032630
View directory record Official record
Conditions
Ischemic Heart Disease
Interventions
Coronary artery bypass - on-pump, Coronary artery bypass - off-pump
Procedure
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
Not listed
Enrollment
2,203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
17
States / cities
Palo Alto, California • San Francisco, California • Sepulveda, California + 14 more
Source: ClinicalTrials.gov public record
Updated May 5, 2014 · Synced Oct 17, 2026, 2:28 PM EDT
Completed Phase 3 Interventional

PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

NCT00048230
View directory record Official record
Conditions
Multiple Myeloma
Interventions
bortezomib
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
Not listed
Enrollment
620 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
39
States / cities
Berkeley, California • Duarte, California • La Jolla, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2012 · Synced Oct 17, 2026, 2:28 PM EDT